Allogene Therapeutics has repeatedly stumbled in its efforts to develop the first off-the-shelf CAR-T therapy for B-cell lymphoma, but is now touting preclinical data suggesting its platform could produce a more effective product than already-marketed autologous multiple myeloma CAR-Ts.
That is significant as its lead candidate, ALLO-501A, has yet to demonstrate durable efficacy to match the established autologous CAR-Ts...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

